Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S.
Pettus J, et al. Among authors: christiansen mp.
Nat Med. 2022 Oct;28(10):2092-2099. doi: 10.1038/s41591-022-02011-x. Epub 2022 Oct 3.
Nat Med. 2022.
PMID: 36192552
Free PMC article.
Clinical Trial.